According to a recent LinkedIn post from Lorikeet, the company is spotlighting a discussion on the Be Customer Led podcast about scaling patient support using artificial intelligence. The post describes how telehealth provider Eucalyptus reportedly scaled patient support capacity fourfold without increasing headcount across four countries and regulatory regimes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that Eucalyptus uses AI to handle 60–70% of support tickets end to end, with more complex, sensitive cases routed to human agents, and suggests an aggregate 10‑point increase in customer satisfaction. It also notes that research cited in the conversation indicates patients may be 50% more likely to prefer AI for personal or embarrassing queries, implying AI can expand addressable demand in telehealth support.
From an investor perspective, the post implies that Lorikeet is positioning its AI capabilities toward high‑complexity, regulated healthcare workflows rather than simple FAQ automation, framing AI support as a “hard product problem.” If this approach generalizes, it could support higher-value, defensible deployments that improve unit economics for telehealth operators via labor efficiency and improved patient satisfaction.
The emphasis on regulatory diversity and sensitive patient conversations suggests Lorikeet is targeting use cases with higher switching costs and stronger barriers to entry. For investors, this may indicate a strategic focus on premium, compliance-heavy markets where proven AI outcomes—such as measurable CSAT gains and headcount-neutral scaling—could support pricing power and long-term recurring revenue opportunities.